| Name | Title | Contact Details |
|---|
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.
British Columbia Cancer Foundation and Research Centre is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cary HealthCare L L C is a Cary, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
HOYA Vision Care Canada is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
McKenzie Memorial Hospital is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. McKenzie Memorial Hospital is based in Sandusky, MI. You can find more information on McKenzie Memorial Hospital at www.mckenziehospital.org